Ocular Hypertension - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 104 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Ocular Hypertension - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H2 2014', provides an overview of the Ocular Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ocular Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ocular Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Ocular Hypertension Overview 9
Therapeutics Development 10
Pipeline Products for Ocular Hypertension - Overview 10
Pipeline Products for Ocular Hypertension - Comparative Analysis 11
Ocular Hypertension - Therapeutics under Development by Companies 12
Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes 14
Ocular Hypertension - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Ocular Hypertension - Products under Development by Companies 18
Ocular Hypertension - Products under Investigation by Universities/Institutes 19
Ocular Hypertension - Companies Involved in Therapeutics Development 20
F. Hoffmann-La Roche Ltd. 20
Bausch & Lomb Incorporated 21
Allergan, Inc. 22
Merck & Co., Inc. 23
Santen Pharmaceutical Co., Ltd. 24
Sylentis S.A. 25
Kowa Company, Ltd. 26
Ono Pharmaceutical Co., Ltd. 27
Can-Fite BioPharma Ltd. 28
Asahi Kasei Pharma Corp. 29
Inotek Pharmaceuticals Corporation 30
Aerie Pharmaceuticals, Inc. 31
Otsuka Holdings Co., Ltd. 32
Ocular Therapeutix, Inc. 33
Amakem NV 34
Ocular Hypertension - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
tafluprost - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ripasudil - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(tafluprost + timolol maleate) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
latanoprostene bunod - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AR-13324 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OPC-1085EL - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CF-101 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
trabodenoson - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
latanoprost - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
SYL-040012 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
lomerizine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
RO-5093151 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
latanoprost - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AMA-0076 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ONO-9054 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
ATS-907 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
DE-117 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
travoprost SR - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
(bimatoprost + brimonidine tartrate) - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
(latanoprost + dorzolamide) - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
LX-7101 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
OPA-6566 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
latanoprost SR - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ATS-8535 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Gene Therapy for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Ocular Hypertension - Recent Pipeline Updates 81
Ocular Hypertension - Dormant Projects 95
Ocular Hypertension - Discontinued Products 96
Ocular Hypertension - Product Development Milestones 97
Featured News & Press Releases 97
Aug 15, 2014: Santen Files for Manufacturing/Marketing Approval of its Glaucoma and Ocular Hypertension Therapeutic, COSOPT Mini Combination Ophthalmic Solution 97
Mar 10, 2014: Inotek Pharmaceuticals Initiates Phase 2 Study with Trabodenoson in Combination with Latanoprost for Patients with Glaucoma or Ocular Hypertension 97
Jan 30, 2014: Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension 98
Jan 15, 2014: Fish & Richardson Wins Patent Infringement Suit for Allergan Over Generic LUMIGAN 0.01% 99
Dec 20, 2013: Alcon Laboratories Receives CHMP Positive Opinion For Izba 100
Oct 10, 2013: Santen Announces the Launch of TAPROS MINI Ophthalmic Solution 0.0015% for Glaucoma and Ocular Hypertension 100
Sep 20, 2013: Santen Announced Approval for TAPCOM Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension 101
May 03, 2013: Amakem To Present Additional Data On AMA0076 At ARVO Annual Meeting 101
Feb 19, 2013: Sucampo Announces Commercial Availability Of Rescula In US Pharmacies 102
Jan 18, 2013: Santen Pharma Receives Japanese Approval For Tapros Mini Ophthalmic Solution 0.0015% For Glaucoma And Ocular Hypertension Treatment 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 104
Disclaimer 104

List of Tables
Number of Products under Development for Ocular Hypertension, H2 2014 10
Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 20
Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2014 21
Ocular Hypertension - Pipeline by Allergan, Inc., H2 2014 22
Ocular Hypertension - Pipeline by Merck & Co., Inc., H2 2014 23
Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 24
Ocular Hypertension - Pipeline by Sylentis S.A., H2 2014 25
Ocular Hypertension - Pipeline by Kowa Company, Ltd., H2 2014 26
Ocular Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 27
Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2014 28
Ocular Hypertension - Pipeline by Asahi Kasei Pharma Corp., H2 2014 29
Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 30
Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2014 31
Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 32
Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2014 33
Ocular Hypertension - Pipeline by Amakem NV, H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Assessment by Combination Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 39
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 46
Ocular Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 81
Ocular Hypertension - Dormant Projects, H2 2014 95
Ocular Hypertension - Discontinued Products, H2 2014 96